Senate Finance Drug Pricing Bill May Gain Traction As Panel’s Lead Health Staffer Joins CMS
Executive Summary
Arielle Woronoff joins the Biden Administration after four years of steering health policy at the Senate Finance Committee, including work on the Grassley-Wyden bill.
You may also be interested in...
Calls For National Tech Assessment Program Could Be Amplified By Costs Of Cell, Gene Therapy
Speculation is growing that the Institute for Clinical and Economic Review or something like it could become the US version of the government-sponsored health tecnology assessment bodies in Europe.
Medicaid Rebate Reform: A Sign Of Minimal Drug Pricing Threats Or A Warning Of More To Come?
House Democrats push to remove the current limit on Medicaid rebates in upcoming COVID-19 relief package would likely leave many drug companies unscathed, but some expect bigger ticket drug pricing items will soon be on the agenda.
Medicare Could Save More than $80bn With Price Inflation Rebates – CBO Score of Senate Bill
Nearly $70bn in savings over 10 years is expected to result from mandatory price inflation rebates for drugs covered by Medicare Part D.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: